PSTX - Poseida Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
PSTX price evolution
PSTX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $30.55 | $53.3 | $44.47 | |
| Short term investments | $207.27 | $145.35 | $167.73 | |
| Net receivables | $14.75 | $12.43 | $12.03 | $9.01 |
| Inventory | ||||
| Total current assets | $250.7 | $254.34 | $216.73 | $226.47 |
| Long term investments | ||||
| Property, plant & equipment | $36.42 | $37.72 | $39.22 | $40.78 |
| Goodwill & intangible assets | $5.55 | $5.55 | $5.55 | |
| Total noncurrent assets | $44.35 | $45.85 | $47.41 | |
| Total investments | $207.27 | $145.35 | $167.73 | |
| Total assets | $293.58 | $298.69 | $262.58 | $273.88 |
| Current liabilities | ||||
| Accounts payable | $5.2 | $2.99 | $2.7 | $3.27 |
| Deferred revenue | $118.21 | $61.67 | $47.79 | |
| Short long term debt | $6.04 | $6 | $5.95 | |
| Total current liabilities | $78.27 | $102.43 | $84.76 | $71.32 |
| Long term debt | $58.91 | $77.61 | $78.57 | $79.47 |
| Total noncurrent liabilities | $135.44 | $93.22 | $98.87 | |
| Total debt | $83.65 | $84.56 | $85.42 | |
| Total liabilities | $206.37 | $237.87 | $177.99 | $170.18 |
| Shareholders' equity | ||||
| Retained earnings | -$629.7 | -$649.94 | -$618.57 | -$594.29 |
| Other shareholder equity | $0.38 | -$0.08 | -$0.05 | $0.13 |
| Total shareholder equity | $60.82 | $84.59 | $103.7 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $44.47 | $81.38 | $206.32 | $83.97 |
| Short term investments | $167.73 | $201.12 | $225.19 | |
| Net receivables | $9.01 | $9.09 | ||
| Inventory | ||||
| Total current assets | $226.47 | $298.56 | $213.87 | $314 |
| Long term investments | ||||
| Property, plant & equipment | $40.78 | $46.67 | $48.23 | $48.32 |
| Goodwill & intangible assets | $5.55 | $5.55 | $5.55 | $5.55 |
| Total noncurrent assets | $47.41 | $53.27 | $55.44 | $57.49 |
| Total investments | $167.73 | $201.12 | $225.19 | |
| Total assets | $273.88 | $351.84 | $269.31 | $371.48 |
| Current liabilities | ||||
| Accounts payable | $3.27 | $2.23 | $8.96 | $0.76 |
| Deferred revenue | $47.79 | $41.06 | $13.76 | |
| Short long term debt | $5.95 | $5.87 | $6.34 | $4.81 |
| Total current liabilities | $71.32 | $53.88 | $43.34 | $30.02 |
| Long term debt | $79.47 | $58.25 | $54.86 | $54.51 |
| Total noncurrent liabilities | $98.87 | $110.36 | $69.76 | $79.49 |
| Total debt | $85.42 | $88.75 | $61.2 | $59.31 |
| Total liabilities | $170.18 | $164.24 | $113.1 | $109.52 |
| Shareholders' equity | ||||
| Retained earnings | -$594.29 | -$470.86 | -$406.86 | -$281.88 |
| Other shareholder equity | $0.13 | -$0.15 | $0.01 | |
| Total shareholder equity | $103.7 | $187.59 | $156.21 | $261.97 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $71.75 | $25.97 | $28.14 | $25 |
| Cost of revenue | ||||
| Gross Profit | $25.97 | $28.14 | $25 | |
| Operating activities | ||||
| Research & development | $45.55 | $42.92 | $42.05 | |
| Selling, general & administrative | $12.18 | $9.8 | $8.86 | |
| Total operating expenses | $52.01 | $57.73 | $52.72 | $50.9 |
| Operating income | -$31.76 | -$24.58 | -$25.91 | |
| Income from continuing operations | ||||
| EBIT | -$29.11 | -$22.02 | -$23.08 | |
| Income tax expense | $0.04 | |||
| Interest expense | -$2.29 | $2.26 | $2.25 | $2.27 |
| Net income | ||||
| Net income | $20.23 | -$31.37 | -$24.27 | -$25.35 |
| Income (for common shares) | -$31.37 | -$24.27 | -$25.35 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $64.7 | $130.49 | $31.24 | |
| Cost of revenue | ||||
| Gross Profit | $64.7 | $130.49 | $31.24 | |
| Operating activities | ||||
| Research & development | $156.77 | $152.9 | $136.73 | $103.52 |
| Selling, general & administrative | $37.44 | $37.54 | $35.91 | $23.03 |
| Total operating expenses | $194.21 | $190.44 | $172.65 | $126.55 |
| Operating income | -$129.5 | -$59.95 | -$141.41 | -$126.55 |
| Income from continuing operations | ||||
| EBIT | -$114.65 | -$57.09 | -$121.62 | -$126.27 |
| Income tax expense | $0.11 | $0.54 | ||
| Interest expense | $8.67 | $6.37 | $3.36 | $3.51 |
| Net income | ||||
| Net income | -$123.43 | -$64 | -$124.97 | -$129.78 |
| Income (for common shares) | -$123.43 | -$64 | -$124.97 | -$129.78 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$31.37 | -$24.27 | -$25.35 | |
| Operating activities | ||||
| Depreciation | $1.35 | $1.38 | $1.44 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.63 | $5.38 | $5.06 | |
| Total cash flows from operations | $38.45 | -$15.13 | -$28.74 | |
| Investing activities | ||||
| Capital expenditures | -$1.02 | -$0.13 | -$0.31 | |
| Investments | -$60.18 | $24.13 | $48.02 | |
| Total cash flows from investing | -$9.55 | -$61.2 | $24 | $47.71 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.7 | -$0.04 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $4.87 | -$22.75 | $8.82 | $18.97 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$123.43 | -$64 | -$124.97 | -$129.78 |
| Operating activities | ||||
| Depreciation | $5.61 | $5.17 | $4.55 | $2.59 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $23.13 | $18.93 | $16.7 | $7.22 |
| Total cash flows from operations | -$92.17 | -$26.77 | -$102.54 | -$113.33 |
| Investing activities | ||||
| Capital expenditures | -$3.07 | -$3.91 | -$2.62 | -$16.91 |
| Investments | $42.2 | -$199.42 | $225 | -$187.52 |
| Total cash flows from investing | $39.13 | -$203.33 | $222.38 | -$204.43 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.35 | $75.3 | $2.52 | $310.11 |
| Net borrowings | $28.55 | -$0.33 | ||
| Total cash flows from financing | $16.13 | $105.16 | $2.52 | $313.94 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$36.91 | -$124.95 | $122.36 | -$3.82 |
News
Fundamentals
| Market cap | $920.54M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 97.41M |
| Revenue | $150.86M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$60.76M |
| Revenue Q/Q | 667.19% |
| Revenue Y/Y | 203.18% |
| P/E ratio | -15.15 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.10 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.62 |
|---|---|
| ROA | -21.53% |
| ROE | N/A |
| Debt/Equity | 1.64 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.20 |
| Quick ratio | N/A |